Artificial intelligence (AI) software developer Quantib has garnered U.S. Food and Drug Administration (FDA) clearance for an AI application designed to assist radiologists in interpreting prostate MRI exams.
The zero-footprint software features a suite of tools, including an image-based calculation of prostate-specific antigen density that's automatically incorporated into the final report, according to the vendor. The application is the sixth from Quantib to receive FDA clearance.
Quantib's prostate AI software features a suite of tools aimed at improving radiologist performance in assessing prostate MRI exams.It also provides a biparametric heat map representation that highlights suspicious areas for radiologists. What's more, the software enables assessment of regions of interests and determination of the PI-RADS score, while also standardizing reporting, Quantib said.
The firm said it plans to deploy the software in 10 facilities this year; a waitlist will be opened for 2021. Enhanced features are also being developed and will be made available on the software over the coming months, according to Quantib.
